⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19267416 | 1.00 | — | — | |
| SCHEMBL19267231 | 1.00 | — | — | |
| SCHEMBL16406103 | 0.82 | ALDH1A1 (0.39) | — | |
| Methyl Alcohol SCHEMBL9267065 | 0.81 | ALDH1A1 (0.42) | — | |
| SCHEMBL15334614 | 0.80 | ALDH1A1 (0.40) | — | |
| SCHEMBL2096176 | 0.76 | — | — | |
| SCHEMBL5959974 | 0.76 | ALDH1A1 (0.42) | — | |
| SCHEMBL20738697 | 0.76 | — | — | |
| SCHEMBL2926049 | 0.76 | — | — | |
| SCHEMBL11878351 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236608-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-07-24 | — | — | US | disclosed |
| WO-2025036241-A1 | COMPOUNDS AND METHODS FOR MODULATING RNA SPLICING | RIBOPEUTIC INC. (CN) | 2025-02-20 | — | — | WO | disclosed |
| US-20240059698-A1 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-02-22 | — | — | US | disclosed |
| WO-2024026056-A2 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026056-A2 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| CN-114727987-A | Substituted heterocyclic compounds having HIV therapeutic activity | 纽约血库公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2020214740-A9 | CHIRAL INDOLE COMPOUNDS AND THEIR USE | ARIAGEN, INC. (US) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020214740-A1 | CHIRAL INDOLE COMPOUNDS AND THEIR USE | ARIAGEN, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| US-9340530-B2 | Preparation and use of bicyclic himbacine derivatives as PAR-1 receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150025046-A1 | PREPARATION AND USE OF BICYCLIC HIMBACINE DERIVATIVES AS PAR-1 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2015-01-22 | — | — | US | disclosed |
| EP-1828207-B1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-10-28 | — | — | EP | disclosed |
| US-20090233919-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-09-17 | — | — | US | disclosed |
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1828207-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-09-05 | — | — | EP | disclosed |
| CN-101001852-A | Pyrazole derivatives | DAIICHI SEIYAKU CO (JP) | 2007-07-18 | — | — | CN | disclosed |
| EP-1785418-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006066174-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-06-22 | — | — | WO | disclosed |
| US-3956325-A | ANTISECRETARY AGENTS | SMITHKLINE CORPORATION (US) | 1976-05-11 | — | — | US | disclosed |
| US-3932641-A | THIOACETAMIDES | SMITHKLINE CORPORATION (US) | 1976-01-13 | — | — | US | disclosed |
| US-3931162-A | N-Aminomethyl heterocyclic thioacetamides | SMITHKLINE CORPORATION (US) | 1976-01-06 | — | — | US | disclosed |